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Editor:
In the August 2015 issue of Radiology, 
Drs Chapiro and Geschwind, in their 
commentary entitled “Science to Prac-
tice: The Changing Face of Local Tu-
mor Therapies—Do We Have to Think 
Systemically When Treating Cancer 
Locally?” (1), highlighted the actual 
need of a better comprehension of the 
systemic effects of local tumor ablation, 
challenging the interventional oncology 
community to work on adjuvant therapy 
to counter this new and relevant prob-
lem. This commentary was in reference 
to recent studies that reported that lo-
cal ablation may stimulate distant tu-
mor growth (2,3). Rozenblum et al (3) 
showed an increased tumor load and re-
duced survival after ablation of 3.5% of 
the liver in comparison to controls in 
an animal model. They identified pro-
regenerative pathways that can trigger 
tumor growth stimulation after ablation. 
They also demonstrated how a molec-
ularly targeted approach could reduce 
the pro-oncogenic effect of ablation.
Although these articles (2,3) present 
strong evidence of the pro-oncogenic 
systemic effect of local ablations, there 
is another side of the issue that should 
be considered. Other studies have high-
lighted the observation that local abla-
tion may stimulate an immune response 
that can ultimately contribute to tu-
mor control (4–6). It has been postu-
lated that thermal ablation of a tumor, 
by determining an exposure of tumoral 
antigens, may trigger a sort of “in vivo 
vaccination” against tumor (4–6), with 
the production of antibodies that can 
contribute to local tumor eradication, 
control of distant metastases, and es-
tablishment of an antitumor immuno-
logical memory (4). Cases of regression 
of distant metastases after ablation have 
been reported (6–8). This phenomenon 
has been referred to as “antitumoral in-
duced immunity.” Sánchez-Ortiz et al 
(6) reported the disappearance of a lung 
metastasis after ablation of the primary 
renal tumor, Kim et al (7) the regression 
of pulmonary and adrenal metastases af-
ter ablation of a recurrent renal carci-
noma, and Rao et al (8) the regression 
of multiple pulmonary metastases after 
ablation of a single metastasis.
Thus, further understanding the full 
range of systemic effects of local abla-
tive therapies and the balance between 
the pro-oncogenic effect and the immu-
no-mediated antitumoral effect will be 
crucial in identifying the optimal treat-
ment to patients and will present an ex-
citing challenge to investigators in the 
upcoming years.
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We read with great interest and appre-
ciation the letter by Dr Mauri and col-
leagues written in response to the article 
by Rozenblum et al titled “Oncogenesis: 
An “Off-Target” Effect of Radiofrequency 
Ablation” (1) and our associated Science 
to Practice commentary (2).
We thank Dr Mauri and colleagues 
for pointing out that the inflammatory 
and systemic effects of radiofrequency 
ablation and other interventional oncol-
ogy therapies are likely to extend beyond 
liver regeneration and tumorigenesis—
the primary focus of our article and edi-
torial. Dr Mauri and colleagues are cor-
rect to note that some evidence exists in 
support of a positive immune response 
to thermal tumor ablation, which might 
very well trigger “abscopic” anti-tumor 
effects by means of tumor antigen ex-
posure. Yet, in comparison to the fairly 
detailed mechanistic evidence in support 
of protumorigenic “off-target” effects of 
thermal ablation presented in this work, 
to date only limited mechanistic evidence 
regarding abscopic effects is available.
We acknowledge the need for fur-
ther study of both potential postabla-
tion pathways and specifically support 
the call to further investigate a broad 
variety of potential positive and nega-
tive downstream effects of intervention-
al oncology procedures. Accordingly, it 
will be up to the scientific community 
to define under what conditions each 
reaction predominates as the ablation 
device selected, tumor and organ types, 
and immune status of the patient are 
likely to influence the balance between 
immunologic and tumorigenic second-
ary effects of interventional oncology 
therapies. Only such study will enable 
us to effectively tailor our therapeutic 
regimens on what is likely to be a pa-
tient-by-patient basis to achieve what 
we believe ought to be the overall pri-
mary objective—maximizing success by 
achieving optimal clinical outcomes.
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Editor:
We read with interest the article by Dr 
Radbruch and colleagues in the June 
2015 issue of Radiology investigating 
gadolinium deposition in the brains of 
patients with repeated gadolinium ex-
posure (1) along with the follow-up ed-
itorial by Kanal and Tweedle (2) in the 
same issue.
Dr Radbruch and colleagues describe 
their elegant study of patients who re-
ceived multiple doses of gadoterate 
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meglumine or gadopentatate dimeglu-
mine. A statistically significant and dose-
dependent increase in precontrast T1-
weighted signal intensity was seen in the 
deep nuclei of the brain after exposure 
to gadopentatate, but not gadoterate. 
This adds to observations of gadolinium 
deposition in patients receiving multi-
ple doses of gadolinium and raises ques-
tions regarding the long-term safety of 
repeated exposures.
However, we are concerned that 
history may be repeating itself to the 
detriment of our patients. Nephrogen-
ic systemic fibrosis (NSF) is a serious 
condition with convincing paired data 
relating NSF to gadolinium exposure in 
renal failure. After NSF was identified, 
there was a lengthy period of uncer-
tainty based on a lack of reliable data. 
The lack of data contributed to an un-
precedented gadolinium-phobia and 
denial of medically important imaging 
studies. The overall impact on human 
health from denial of imaging will never 
be known, but in our opinion likely ex-
ceeded the potential risks of NSF.
Unlike NSF, gadolinium deposition, 
although concerning, lacks paired evi-
dence of adverse neurologic or biologic 
outcomes. Therefore, we are not able 
to comprehend which, if any, practi-
cal recommendations are appropriate 
at this stage. We also suggest caution 
in concluding that gadolinium reten-
tion is “dependent on the class of con-
trast agent.” Although findings from re-
cent publications are consistent with 
this statement (1,3), we find this broad 
conclusion premature, as additional 
work evaluating all agents is needed. Is 
it prudent to switch preferentially to a 
class of pharmaceutical agents, some 
of which are expensive, purely on the 
basis of imaging observations? This is 
fraught with potential for abuse from 
pharmaceutical companies and legal 
firms to seize on this controversy to 
their financial benefit.
We are reminded of the adage: 
“Treat the patient, not the picture.”
We urge caution in the interpreta-
tion of these data. Additional studies 
are warranted, but the development of 
“practical implications” such as with-
their constructive criticism. We agree 
on a lot of—however, not on all—the 
points raised by Drs Reeder and Gulani.
First, we concur that the entirety of 
the marketed gadolinium-based contrast 
agents (GBCAs) has to be assessed in 
order to conclude that a signal intensity 
increase in the deep nuclei is dependent 
on the class of contrast agent. In our ar-
ticle, we have taken this into account by 
stating that “only two of the nine avail-
able GBCAs on the market have been 
analyzed” (1) and by concluding that 
future studies including other GBCAs 
should be conducted. Nonetheless, con-
sidering all evidence from the hitherto 
published in vitro (2) and in vivo (1, 
3–10) data (with the exception of one 
recently published study [11]), we hy-
pothesize that the differentiation in mac-
rocyclic and linear GBCAs is most likely 
the crucial factor when looking at causes 
for a potential signal intensity increase 
in the deep nuclei (12), even though this 
is not proven yet.
Second, we agree that gadolinium 
deposition in the deep nuclei “lacks 
paired evidence of adverse neurologic 
or biologic outcomes” and clearly state 
this in our article. However, it should 
also be mentioned that clinically rele-
vant sequalae of gadolinium retention 
in the brain cannot be excluded and—
given the fact that there is histologi-
cally proved accumulation in the brain 
(7,8)—it is important to prove that 
there is no clinical damage rather than 
to prove that there is damage.
Third, we agree that the findings of 
gadolinium deposition in the brain can 
potentially cause a “gadolinium-pho-
bia.” However, we are convinced that 
the best way to manage this scenario is 
to continue conducting evidence-based 
studies and—just as important—to pro-
vide our patients with comprehensive 
information about the contrast agent 
they receive. This includes the varying 
potential of GBCAs to cause hyperin-
tensities in the deep nuclei in the brain, 
the currently unknown clinical rele-
vance of these hyperintensities, and the 
varying prices of the contrast agents. 
Only by proactively addressing the is-
sue of gadolinium retention in the brain 
holding gadolinium or promoting mac-
rocyclic agents is premature.
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We thank Drs Reeder and Gulani for the 
appreciation of our work as well as for 
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will we be able to prevent the unrea-
sonable decline of gadolinium-enhanced 
magnetic resonance (MR) imaging.
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We thank Drs Reeder and Gulani for 
their insightful comments. We agree that 
unwarranted fear of GBCA is inappropri-
ate and potentially harmful. Drs Reeder 
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is “concerning.” Common sense demands 
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of reasonable and readily implementable 
steps, such as prescribing agents that 
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per administered dose.
We also concur that concluding at 
this point that IGA is dependent on the 
contrast agent class is premature. We 
therefore carefully avoided such conclu-
sions and insist on further studies before 
sound conclusions can be drawn. This is 
especially imperative now that the liter-
ature has documented that one macro-
cyclic agent is associated with these ef-
fects (1) whereas two other macrocycles 
may not be (2,3). Moreover, some linear 
agents exhibit these effects to a greater 
extent than do others (3–6).
We also wish to “treat the patient, 
not the picture.” We don’t advocate 
treating images, but rather responding 
to the new pharmacokinetic data they 
revealed, namely, marked differences in 
IGA following administration of various 
GBCAs. This was not considered in the 
past but, appropriately, is a focus of our 
attention today.
We have known for years (7,8) that 
gadolinium retention in bone differs 
among various GBCAs. This reinforces 
our concern regarding differential IGA.
We therefore respond to the ques-
tion in their letter title, “Do we know 
enough to change practice?” with a re-
sounding “Yes.”
We agree that “withholding gadolin-
ium or promoting macrocyclic agents is 
premature,” and made no such recom-
mendations. But withholding gadolini-
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reasonable, common sense, and easily 
implementable recommendations until 
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Radiologists should therefore be-
come more involved in deciding (a) 
whether to administer a GBCA, (b) 
which agent should be administered to 
which patient, and (c) the administered 
dose for each patient for whom a con-
trast material–enhanced MR examina-
tion is clinically requested.
Our patients would expect no less 
of us.
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Editor:
I read with interest the article by Dr 
Yun and colleagues in the March 2015 
issue of Radiology entitled “Glioblas-
toma Treated with Concurrent Radia-
tion Therapy and Temozolomide Che-
motherapy: Differentiation of True 
Progression from Pseudoprogression 
with Quantitative Dynamic Contrast-en-
hanced MR Imaging” (1). The authors 
demonstrated that mean volume trans-
fer constant (Ktrans) and extravascular 
extracellular space per unit volume of 
tissue (ve) in true progression were sig-
nificantly higher than those in pseudo-
progression; however, the blood plasma 
volume per unit volume of tissue (vp) 
was not significantly different between 
the true progression and pseudopro-
gression groups. vp may be a marker of 
angiogenic activity in a tumor, and the 
lack of difference in vp is somewhat un-
expected and can be related to the to-
tal image acquisition time in this study, 
which was 1 minute 30 seconds. Lars-
son et al (2) investigated the effect of 
variations in total measurement times 
on the estimations of kinetic parame-
ters derived from dynamic contrast-en-
hanced magnetic resonance (MR) im-
aging by using acquisition times of 1, 2, 
3, 4, and 5 minutes and demonstrated 
that reduced total sampling time will 
result in reduced precision of the es-
timated values with overestimation of 
Ktrans and the constant of transfer from 
the interstitial space to the plasma (Kep) 
and underestimation of vp and ve (2). 
In fact, although there are some vari-
ations in the literature with regard to 
total image acquisition time in dyam-
ic contrast-enhanced MR imaging, the 
more common acquisition time in the 
literature as well as my institution is ap-
proximately 5 minutes (3,4). Therefore, 
I believe that the results of this study 
should be interpreted with caution and 
that further studies with long acquisi-
tion times as well as cross validation of 
the results in a prospective study are 
warranted.
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Editor:
We were pleased to read the very in-
teresting article in the September 2015 
issue of Radiology by Dr Nougaret and 
colleagues (1), who underlined that 
the major clinical challenge in endo-
metrial cancer staging is to select the 
patients who are most likely to bene-
fit from lymphadenectomy. This is par-
ticularly relevant in patients with type 
1 endometrial cancer, as patients with 
type 2 cancer do require systematic pel-
vic and para-aortic lymphadenectomy 
(2). Moreover, tumor size and lympho-
vascular space involvement (LVSI) have 
no impact on survival in patients with 
type 2 endometrial cancer (3,4). There-
fore, it is of particular interest to deter-
mine the contribution of magnetic reso-
nance (MR) imaging in a homogeneous 
population of patients with type 1 en-
dometrial cancer (59 of 70 patients in 
this study). In these patients with type 
1 cancer, European Society for Medical 
Oncology (ESMO) guidelines state that 
patients with low or intermediate risk of 
recurrence who exhibit LVSI should be 
considered a high-risk group (2). In the 
study by Dr Nougaret and colleagues, a 
very high percentage of patients under-
went para-aortic lymph node sampling 
(89%), which is commonly indicated in 
high-risk patients, who typically have 
comprised less than one-quarter of pa-
tients with early stage disease in previ-
ous retrospective studies (3,5). More-
over, in this study, there was a high level 
of LVSI (50% vs 20%–30% in previous 
studies) (3,5). Thus, it would be very 
helpful to understand in which ESMO 
category the patients in this study were 
initially classified and in how many cases 
the new MR imaging criteria evaluated 
would have modified management.
Second, in their study, Dr Nouga-
ret and colleagues conclude that the dif-
ferent MR pulse sequences were equal 
in the evaluation of tumor size because 
nonsignificant differences were found. 
Did the authors have a sufficient study 
size to draw this conclusion? For that 
issue, the measurement of the concor-
dance between size at histologic and MR 
examination would have been helpful. Is 
this histologic information available?
Finally, Dr Nougaret and colleagues 
compared the accuracy of a number of 
MR pulse sequences in the evaluation of 
myometrial invasion. It is surprising that 
the authors did not compare T2- and dif-
fusion-weighted pulse sequences with a 
high-spatial-resolution T1-weighted pulse 
sequence, which is considered as a stan-
dard in European guidelines (6). More-
over, the number of premenopausal and 
menopausal patients and the presence of 
benign uterine-associated abnormalities 
would be useful to discuss in the assess-
ment of myometrial invasion.
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We thank Dr Thomassin-Naggara and 
colleagues for their thoughtful com-
ments regarding our article (1).
First, as they point out, a large per-
centage of patients in our study un-
derwent para-aortic lymph node sam-
pling. The decision to proceed with 
para-aortic lymph node sampling was 
based on a combination of factors, 
including preoperative tumor grade, 
imaging findings, intraoperative as-
sessment, and surgical templates in 
practice at our institution during the 
study period (2010–2012). We would 
like to emphasize that the current sur-
gical practices are a product of ongo-
ing revisions based on emerging new 
data and that these practices have un-
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dergone changes since the time of our 
retrospective data review. Further-
more, unfortunately, there is no single 
universally accepted surgical approach 
for the treatment of endometrial carci-
noma, and the practice remains non-
uniform between Europe and North 
America, as well as amongst different 
institutions within North America.
Second, as Dr Thomassin-Naggara 
and colleagues accurately note, 50% of 
patients in our cohort had LVSI, which 
is higher than that in other reports. 
This may be explained by the fact that 
we selected patients with tumors that 
were large enough to undergo quanti-
tative assessment with MR volumetry.
Third, we could not directly corre-
late tumor volumes at MR imaging to 
those at histopathologic examination 
because this information was not con-
sistently available at the time of our ret-
rospective data review.
Fourth, we would like to direct Dr 
Thomassin-Naggara and colleagues 
to table 5 and to the “Qualitative As-
sessment of Myometrial Invasion” sec-
tion under Results for further infor-
mation regarding the comparison of 
T2-weighted imaging with diffusion-
weighted imaging and T2-weighted 
imaging with contrast-enhanced T1-
weighted imaging in the assessment of 
myometrial invasion. We did not per-
form a subgroup analysis to examine 
the influence of various confounding 
factors such as menopausal status and 
benign uterine abnormalities on the 
performance of MR imaging for the 
assessment of myometrial invasion be-
cause this analysis was previously re-
ported by Beddy et al (2).
Finally, in this study we aimed to 
investigate the value of quantitative tu-
mor volume measurements and whole 
tumor volume apparent diffusion coef-
ficient histogram metrics as predictive 
biomarkers of the depth of myometrial 
invasion, tumor grade, and LVSI at sur-
gery. Although beyond the scope of our 
study, we concur with Dr Thomassin-
Naggara and colleagues that it would 
be of interest for future studies to in-
vestigate how quantitative MR imaging 
criteria could influence surgical man-
agement of endometrial carcinoma in 
accordance with ESMO practice guide-
lines (3).
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Incorrect Learning Objectives were 
published with the print article. 
The Learning Objectives should be 
as follows: Describe correct MR 
imaging technique for assessment 
of labroligamentous injuries of the 
shoulder; Define common labral 
variants that can simulate injury; 
Discuss examples of sequelae of 
traumatic instability; Describe the 
SLAP tear and its major compo-
nents; Discuss the concepts of 
external and internal impingement 
and their major subcategories; De-
scribe the common nerve entrap-
ment syndromes and their major 
imaging characteristics.
